Abstract
Platinum-based doublets are the cornerstone of treatment in advanced non-small-cell lung cancer (NSCLC) and often include vinorelbine or taxanes. A predictive biomarker is greatly needed to select chemotherapy-sensitive patients for these microtubule-interfering agents. Class III ß-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role of TUBB3 in advanced NSCLC.
Original language | English |
---|---|
Journal | Clinical Cancer Research |
Volume | 17 |
Issue number | 15 |
Pages (from-to) | 5205-14 |
Number of pages | 10 |
ISSN | 1078-0432 |
DOIs | |
Publication status | Published - 2011 |